BR112015006798A2 - vírus da vacínia ankara modificado, genoma, célula, métodos para cultivar um vírus mva, para produzir um vírus mva e para produzir um vírus mva recombinante, composição farmacêutica, vacina, vírus mva ou genoma, e, molécula de ácido nucleico - Google Patents
vírus da vacínia ankara modificado, genoma, célula, métodos para cultivar um vírus mva, para produzir um vírus mva e para produzir um vírus mva recombinante, composição farmacêutica, vacina, vírus mva ou genoma, e, molécula de ácido nucleicoInfo
- Publication number
- BR112015006798A2 BR112015006798A2 BR112015006798A BR112015006798A BR112015006798A2 BR 112015006798 A2 BR112015006798 A2 BR 112015006798A2 BR 112015006798 A BR112015006798 A BR 112015006798A BR 112015006798 A BR112015006798 A BR 112015006798A BR 112015006798 A2 BR112015006798 A2 BR 112015006798A2
- Authority
- BR
- Brazil
- Prior art keywords
- mva virus
- virus
- genome
- mva
- producing
- Prior art date
Links
- 241000700605 Viruses Species 0.000 title abstract 13
- 241000700618 Vaccinia virus Species 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 229960005486 vaccine Drugs 0.000 title abstract 3
- 150000007523 nucleic acids Chemical class 0.000 title abstract 2
- 102000039446 nucleic acids Human genes 0.000 title abstract 2
- 108020004707 nucleic acids Proteins 0.000 title abstract 2
- 238000012258 culturing Methods 0.000 title 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 229940124531 pharmaceutical excipient Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24061—Methods of inactivation or attenuation
- C12N2710/24064—Methods of inactivation or attenuation by serial passage
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Virology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2012/069256 WO2014048500A1 (en) | 2012-09-28 | 2012-09-28 | Novel mva virus and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112015006798A2 true BR112015006798A2 (pt) | 2017-11-21 |
Family
ID=46982581
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015006798A BR112015006798A2 (pt) | 2012-09-28 | 2012-09-28 | vírus da vacínia ankara modificado, genoma, célula, métodos para cultivar um vírus mva, para produzir um vírus mva e para produzir um vírus mva recombinante, composição farmacêutica, vacina, vírus mva ou genoma, e, molécula de ácido nucleico |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9732325B2 (enExample) |
| EP (1) | EP2900810B1 (enExample) |
| JP (1) | JP2015535687A (enExample) |
| CN (1) | CN104812894B (enExample) |
| AU (1) | AU2012391162A1 (enExample) |
| BR (1) | BR112015006798A2 (enExample) |
| CA (1) | CA2885240A1 (enExample) |
| DK (1) | DK2900810T3 (enExample) |
| IN (1) | IN2015DN02335A (enExample) |
| MX (1) | MX2015003687A (enExample) |
| RU (1) | RU2015115898A (enExample) |
| WO (1) | WO2014048500A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3052895A1 (en) * | 2017-02-23 | 2018-08-30 | Probiogen Ag | Vaccinia virus vectors related to modified vaccinia ankara (mva) with extensive genomic symmetries |
| WO2019089755A1 (en) | 2017-10-31 | 2019-05-09 | Western Oncolytics Ltd. | Platform oncolytic vector for systemic delivery |
| CN108371715A (zh) * | 2018-01-03 | 2018-08-07 | 肖小林 | 一种病毒的靶向性防治药物 |
| WO2019216929A1 (en) * | 2018-05-11 | 2019-11-14 | City Of Hope | Mva vectors for expressing multiple cytomegalovirus (cmv) antigens and use thereof |
| US11999975B2 (en) | 2018-07-04 | 2024-06-04 | Probiogen Ag | Method for purifying an enveloped virus |
| PE20231175A1 (es) | 2020-11-19 | 2023-08-01 | Kalivir Immunotherapeutics Inc | Inmunoterapia oncolitica por remodelacion del microambiente tumoral |
| WO2023128672A1 (ko) * | 2021-12-29 | 2023-07-06 | 재단법인 아산사회복지재단 | 외피외 바이러스 생산이 증가한 신규한 백시니아 바이러스 변이주 |
| WO2023223183A1 (en) | 2022-05-16 | 2023-11-23 | Crispr Therapeutics Ag | Picornaviral vectors for gene editing |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7645456B2 (en) * | 2001-04-23 | 2010-01-12 | Sanofi Pasteur Biologics Co. | Vaccinia virus strains |
| EP1601333B1 (en) | 2003-02-20 | 2013-01-23 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services | Novel insertion sites in pox vectors |
-
2012
- 2012-09-28 CN CN201280077370.4A patent/CN104812894B/zh active Active
- 2012-09-28 US US14/431,814 patent/US9732325B2/en active Active
- 2012-09-28 BR BR112015006798A patent/BR112015006798A2/pt not_active IP Right Cessation
- 2012-09-28 JP JP2015533460A patent/JP2015535687A/ja active Pending
- 2012-09-28 DK DK12769398.4T patent/DK2900810T3/en active
- 2012-09-28 AU AU2012391162A patent/AU2012391162A1/en not_active Abandoned
- 2012-09-28 WO PCT/EP2012/069256 patent/WO2014048500A1/en not_active Ceased
- 2012-09-28 IN IN2335DEN2015 patent/IN2015DN02335A/en unknown
- 2012-09-28 CA CA2885240A patent/CA2885240A1/en not_active Abandoned
- 2012-09-28 RU RU2015115898A patent/RU2015115898A/ru not_active Application Discontinuation
- 2012-09-28 MX MX2015003687A patent/MX2015003687A/es unknown
- 2012-09-28 EP EP12769398.4A patent/EP2900810B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2900810A1 (en) | 2015-08-05 |
| DK2900810T3 (en) | 2019-04-29 |
| US9732325B2 (en) | 2017-08-15 |
| US20150299666A1 (en) | 2015-10-22 |
| CN104812894A (zh) | 2015-07-29 |
| CA2885240A1 (en) | 2014-04-03 |
| MX2015003687A (es) | 2015-06-15 |
| CN104812894B (zh) | 2021-10-22 |
| AU2012391162A1 (en) | 2015-04-09 |
| WO2014048500A1 (en) | 2014-04-03 |
| RU2015115898A (ru) | 2016-11-20 |
| JP2015535687A (ja) | 2015-12-17 |
| EP2900810B1 (en) | 2019-02-20 |
| IN2015DN02335A (enExample) | 2015-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015006798A2 (pt) | vírus da vacínia ankara modificado, genoma, célula, métodos para cultivar um vírus mva, para produzir um vírus mva e para produzir um vírus mva recombinante, composição farmacêutica, vacina, vírus mva ou genoma, e, molécula de ácido nucleico | |
| WO2012177924A3 (en) | Influenza virus mutants and uses therefor | |
| BRPI0712158B8 (pt) | processo para produzir uma composição de poxvírus de tipo selvagem, atenuado e/ou recombinante sem especificidade de infecção visada | |
| BRPI1015053A2 (pt) | partículas similares a vírus da influenza quiméricas compreendendo hemaglutinina | |
| BR112018008090A2 (pt) | vacina de vírus do herpes simplex. | |
| BR112018013168A2 (pt) | vírus mutantes, método de preparação e uso dos mesmos | |
| NO20073737L (no) | Hjelp for influensavirus | |
| HK1225631A1 (zh) | 免疫原性中东呼吸综合征冠状病毒(mers-cov)组合物和方法 | |
| BR112014027736A2 (pt) | produção de partícula semelhante a rotavírus em plantas | |
| BRPI0821034A8 (pt) | Vírus influenza b recombinante, seu uso, metodo de preparação, composição de vacina o contendo e seu gene m, bem como ácido nucléico isolado, molécula do vírus influenza m e seu uso e método para aumentar a taxa de crescimento de vírus influenza b deficiente de replicação | |
| MX373096B (es) | Formulaciones virales líquidas. | |
| BR112015006763B1 (pt) | Constructo de ácido nucleico, vetor de transferência plasmídico, partículas de vírus mv-chik, composições, uso da composição, uso das partículas de vírus mv-chik e processo para resgatar vírus do sarampo (mv) recombinante | |
| MX2011007692A (es) | Vacunas mejoradas para el virus del papiloma humano y procedimientos para su utilizacion. | |
| BR112014007474A2 (pt) | aumento de rendimento de partícula tipo vírus em plantas | |
| CA2915027A1 (en) | Compositions and methods for administration of vaccines against dengue virus | |
| BR112014017242A8 (pt) | vlps contendo hpv l2 imunogênico e composições e métodos relacionados | |
| EP3939604A3 (en) | Influenza hemagglutinin protein vaccines | |
| WO2006063053A3 (en) | Methods of producing influenza vaccine compositions | |
| IN2015DN03070A (enExample) | ||
| WO2005115448A3 (en) | Multi plasmid system for the production of influenza virus | |
| WO2013055326A3 (en) | Vaccines for human papilloma virus and methods for using the same | |
| WO2011039180A3 (en) | Novel vaccine composition against influenza | |
| BR112015024391A2 (pt) | mutante de proteína, capsídeo, método para melhorar a estabilidade de um capsídeo, molécula de ácido nucleico isolada, célula hospedeira, micro-organismo recombinante carreador vivo, vacina, uso de um mutante da proteína vp2, e, métodos para preparar uma vacina e um mutante da proteína | |
| MX2024005482A (es) | Vacunas hibridas multivalentes antigripales que comprenden hemaglutinina y neuraminidasa y metodos de uso de las mismas. | |
| BR112018000037A2 (pt) | partículas semelhantes a vírus recombinantes usando a proteína gag do vírus da imunodeficiência bovina (vlp de bgag), vacina, vetor plasmidial de transferência para produzir a vlp de bgag, método para fazer a vlp de bgag, método para preparar a vacina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2447 DE 28-11-2017 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |